PE anti-human CD279 (PD-1) Antibody

Pricing & Availability
Clone
EH12.2H7 (See other available formats)
Regulatory Status
RUO
Other Names
PD-1
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
1_EH12dot2H7_PE_022508
PHA-stimulated (day-3) human peripheral blood lymphocytes were stained with CD279 (clone EH12.2H7) PE (filled histogram) or mouse IgG1, κ PE (open histogram).
  • 1_EH12dot2H7_PE_022508
    PHA-stimulated (day-3) human peripheral blood lymphocytes were stained with CD279 (clone EH12.2H7) PE (filled histogram) or mouse IgG1, κ PE (open histogram).
  • 2_EH12dot2H7_PE_072209.jpg
    Human peripheral blood lymphocytes were stained with CD279 (clone EH12.2H7) PE and CD3 (clone UCHT1) PerCP/Cy5.5.
  • 3_2_Human_LN_IgD_PD-1
    Confocal image of human lymph node sample acquired using the IBEX method of highly multiplexed antibody-based imaging: IgD (blue) in Cycle 2, PD-1 (green) in Cycle 5. Tissues were prepared using ~1% (vol/vol) formaldehyde and a detergent. Following fixation, samples are immersed in 30% (wt/vol) sucrose for cryoprotection. Images are courtesy of Drs. Andrea J. Radtke and Ronald N. Germain of the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
329905 25 tests 97€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
329906 100 tests 212€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Programmed cell death 1 (PD-1), also known as CD279, is a 55 kD member of the immunoglobulin superfamily. CD279 contains the immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic region and plays a key role in peripheral tolerance and autoimmune disease. CD279 is expressed predominantly on activated T cells, B cells, and myeloid cells. PD-L1 (B7-H1) and PD-L2 (B7-DC) are ligands of CD279 (PD-1) and are members of the B7 gene family. Evidence suggests overlapping functions for these two PD-1 ligands and their constitutive expression on some normal tissues and upregulation on activated antigen-presenting cells. Interaction of CD279 ligands results in inhibition of T cell proliferation and cytokine secretion.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human
Reported Reactivity
African Green, Baboon, Chimpanzee, Common Marmoset, Cynomolgus, Rhesus, Squirrel Monkey
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling
The CD279 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
SB - Reported in the literature, not verified in house

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported applications (for the relevant formats) include: blocking of ligand binding1-3, immunohistochemical staining of paraformaldehyde fixed frozen sections13, and spatial biology (IBEX)15,16. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 329911 and 329912). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 329926) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Additional Product Notes

Iterative Bleaching Extended multi-pleXity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).

Application References

(PubMed link indicates BioLegend citation)
  1. Dorfman DM, et al. 2006 Am. J. Surg. Pathol. 30:802. (FA)
  2. Radziewicz H, et al. 2007. J. Virol. 81:2545. (FA)
  3. Velu V, et al. 2007. J. Virol. 81:5819. (FA)
  4. Zahn RC, et al. 2008. J. Virol. 82:11577. PubMed
  5. Chang WS, et al. 2008. J. Immunol. 181:6707. (FC) PubMed
  6. Nakamoto N, et al. 2009. PLoS Pathog. 5:e1000313. (FA)
  7. Jones RB, et al. 2009. J. Virol. 83:8722. (FC) PubMed
  8. Vojnov L, et al. 2010. J. Virol. 84:753. (FC) PubMed
  9. Radziewicz H, et al. 2010. J. Immunol. 184:2410. (FC) PubMed
  10. Monteriro P, et al. 2011. J. Immunol. 186:4618. PubMed
  11. Conrad J, et al. 2011. J. Immunol. 186:6871. PubMed
  12. Salisch NC, et al. 2010. J. Immunol. 184:476. (Rhesus reactivity)
  13. Li H and Pauza CD. 2015. Eur. J. Immunol. 45:298. (IHC)
  14. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
  15. Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed
  16. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Kamiya T, et al. 2018. Blood Adv. 2:517. PubMed
  2. Capuano C, et al. 2018. Front Immunol. 9:1031. PubMed
  3. Wang F, et al. 2018. Oncogenesis. 7:41. PubMed
  4. Wu L, et al. 2018. Oncol Lett. 15:9507. PubMed
  5. Huang L, et al. 2018. Mol Med Rep. 18:77. PubMed
  6. Lin JR et al. 2018. eLife. 7 pii: e31657. PubMed
  7. Findlay EG, et al. 2019. Oncoimmunology. 8:1608106. PubMed
  8. Wei J, et al. 2019. J Immunother Cancer. 7:209. PubMed
  9. Cortés–Rubio CN, et al. 2019. Clin Epigenetics. 11:134. PubMed
  10. Ma X et al. 2019. Cell Metab. 30(1):143-156 . PubMed
  11. Kim CJ, et al. 2018. Immunity. 49:1034. PubMed
  12. Pauthner M et al. 2017. Immunity. 46(6):1073-1088 . PubMed
  13. Wang B, et al. 2018. Mol Ther Nucleic Acids. 0.548611111. PubMed
  14. Li B, et al. 2019. Oncogenesis. 8:17. PubMed
  15. Swadling L, et al. 2020. Cell Rep. 30:687. PubMed
  16. Wang C, et al. 2020. Oncologist. 25:382. PubMed
  17. Good Z, et al. 2019. Nat Biotechnol. 37:259. PubMed
  18. Matsuyama H, et al. 2019. Sci Rep. 9:13181. PubMed
  19. Zhou R, et al. 2020. Immunity. S1074-7613(20)30333-2.. PubMed
  20. Ping Y, et al. 2020. Front Cell Dev Biol. 0.890972222. PubMed
  21. Chang W, et al. 2008. J Immunol. 181:6707. PubMed
  22. Vojnov L, et al. 2010. J Virol. 84:753. PubMed
  23. Radziewicz H, et al. 2010. J Immunol. 184:2410. PubMed
  24. Zhu C, et al. 2012. J Clin Endocrinol Metab. 97:943. PubMed
  25. Raghuraman S, et al. 2012. J Infect Dis. 205:763. PubMed
  26. Suzuki M, et al. 2012. J Immunol. 189:2118. PubMed
  27. Xu Y, et al. 2013. J Virol. 87:3760. PubMed
  28. Xu H, et al. 2013. J Leukoc Biol. 93:943. PubMed
  29. Fujita T, et al. 2014. J Immunol. 193:5576. PubMed
  30. Schumann K, et al. 2015. Proc Natl Acad Sci U S A. 112: 10437-10442. PubMed
  31. Colineau L, et al. 2015. PLoS One. 10: e0140978. PubMed
  32. Pombo C, et al. 2015. J Infect Dis. 12: 1376-1386. PubMed
  33. Karlsson H, et al. 2015. PLoS One. 10: 0144787. PubMed
  34. Nduom E, et al. 2016. Neuro Oncology. 18: 195 - 205. PubMed
  35. Jutz S, et al. 2016. J Immunol Methods. 430:10-20. PubMed
  36. Richter M, et al. 2016. Mol Ther Methods Clin Dev. 5:16013. PubMed
  37. Beyer M, et al. 2016. Nat Immunol. 17:593-603. PubMed
  38. Li H, et al. 2016. J Immunol. 196: 4064 - 4074. PubMed
  39. Rosskopf S, et al. 2016. Sci Rep. 6:31580. PubMed
  40. Diao B, et al. 2020. Front Immunol. 1.032638889. PubMed
  41. Zhang C, et al. 2020. Front Oncol. 0.944444444. PubMed
  42. Li N, et al. 2020. Oncoimmunology. 9:1824643. PubMed
  43. Buggert M, et al. 2020. Cell. 183(7):1946-1961.e15. PubMed
  44. Bonifacius A, et al. 2021. Immunity. 54(2):340-354.e6. PubMed
  45. Shuwa HA, et al. 2021. Med. 2(6):720-735.e4. PubMed
RRID
AB_940481 (BioLegend Cat. No. 329905)
AB_940483 (BioLegend Cat. No. 329906)

Antigen Details

Structure
Immunoglobulin superfamily
Distribution

Transiently expressed on CD4- CD8- thymocytes; upregulated in thymocytes and splenic T and B lymphocytes; expressed on activated myeloid cells

Ligand/Receptor
B7-H1 (also known as PD-L1) and B7-DC (PD-L2)
Cell Type
B cells, Lymphocytes, T cells, Thymocytes, Tregs
Biology Area
Cancer Biomarkers, Immunology, Inhibitory Molecules
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Gene ID
5133 View all products for this Gene ID
UniProt
View information about CD279 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
If an antibody clone has been previously successfully used in IBEX in one fluorescent format, will other antibody formats work as well?

It’s likely that other fluorophore conjugates to the same antibody clone will also be compatible with IBEX using the same sample fixation procedure. Ultimately a directly conjugated antibody’s utility in fluorescent imaging and IBEX may be specific to the sample and microscope being used in the experiment. Some antibody clone conjugates may perform better than others due to performance differences in non-specific binding, fluorophore brightness, and other biochemical properties unique to that conjugate.

Will antibodies my lab is already using for fluorescent or chromogenic IHC work in IBEX?

Fundamentally, IBEX as a technique that works much in the same way as single antibody panels or single marker IF/IHC. If you’re already successfully using an antibody clone on a sample of interest, it is likely that clone will have utility in IBEX. It is expected some optimization and testing of different antibody fluorophore conjugates will be required to find a suitable format; however, legacy microscopy techniques like chromogenic IHC on fixed or frozen tissue is an excellent place to start looking for useful antibodies.

Are other fluorophores compatible with IBEX?

Over 18 fluorescent formats have been screened for use in IBEX, however, it is likely that other fluorophores are able to be rapidly bleached in IBEX. If a fluorophore format is already suitable for your imaging platform it can be tested for compatibility in IBEX.

The same antibody works in one tissue type but not another. What is happening?

Differences in tissue properties may impact both the ability of an antibody to bind its target specifically and impact the ability of a specific fluorophore conjugate to overcome the background fluorescent signal in a given tissue. Secondary stains, as well as testing multiple fluorescent conjugates of the same clone, may help to troubleshoot challenging targets or tissues. Using a reference control tissue may also give confidence in the specificity of your staining.

How can I be sure the staining I’m seeing in my tissue is real?

In general, best practices for validating an antibody in traditional chromogenic or fluorescent IHC are applicable to IBEX. Please reference the Nature Methods review on antibody based multiplexed imaging for resources on validating antibodies for IBEX.

Other Formats

View All CD279 Reagents Request Custom Conjugation
Description Clone Applications
Brilliant Violet 421™ anti-human CD279 (PD-1) EH12.2H7 FC
Purified anti-human CD279 (PD-1) EH12.2H7 FC, Block, IHC-F
FITC anti-human CD279 (PD-1) EH12.2H7 FC
PE anti-human CD279 (PD-1) EH12.2H7 FC, SB
APC anti-human CD279 (PD-1) EH12.2H7 FC
Alexa Fluor® 647 anti-human CD279 (PD-1) EH12.2H7 FC
PerCP/Cyanine5.5 anti-human CD279 (PD-1) EH12.2H7 FC
APC/Cyanine7 anti-human CD279 (PD-1) EH12.2H7 FC
Pacific Blue™ anti-human CD279 (PD-1) EH12.2H7 FC
PE/Cyanine7 anti-human CD279 (PD-1) EH12.2H7 FC
Purified anti-human CD279 (PD-1) (Maxpar® Ready) EH12.2H7 FC, CyTOF®
Brilliant Violet 605™ anti-human CD279 (PD-1) EH12.2H7 FC
Ultra-LEAF™ Purified anti-human CD279 (PD-1) EH12.2H7 FC, Block, IHC-F
Brilliant Violet 711™ anti-human CD279 (PD-1) EH12.2H7 FC
Brilliant Violet 785™ anti-human CD279 (PD-1) EH12.2H7 FC
Brilliant Violet 510™ anti-human CD279 (PD-1) EH12.2H7 FC
Biotin anti-human CD279 (PD-1) EH12.2H7 FC
PE/Dazzle™ 594 anti-human CD279 (PD-1) EH12.2H7 FC
Alexa Fluor® 488 anti-human CD279 (PD-1) EH12.2H7 FC
PerCP anti-human CD279 (PD-1) EH12.2H7 FC
GoInVivo™ Purified anti-human CD279 (PD-1) EH12.2H7 FC, Block, IHC
Brilliant Violet 650™ anti-human CD279 (PD-1) EH12.2H7 FC
Alexa Fluor® 700 anti-human CD279 (PD-1) EH12.2H7 FC
APC/Fire™ 750 anti-human CD279 (PD-1) EH12.2H7 FC
TotalSeq™-A0088 anti-human CD279 (PD-1) EH12.2H7 PG
TotalSeq™-B0088 anti-human CD279 (PD-1) EH12.2H7 PG
TotalSeq™-C0088 anti-human CD279 (PD-1) EH12.2H7 PG
Brilliant Violet 750™ anti-human CD279 (PD-1) EH12.2H7 FC
TotalSeq™-D0088 anti-human CD279 (PD-1) EH12.2H7 PG
PE/Fire™ 640 anti-human CD279 (PD-1) EH12.2H7 FC
PE/Cyanine5 anti-human CD279 (PD-1) EH12.2H7 FC
Go To Top Version: 3    Revision Date: 04/19/2022

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

  • Brilliant Violet 421™ anti-human CD279 (PD-1)

  • Purified anti-human CD279 (PD-1)

  • FITC anti-human CD279 (PD-1)

  • PE anti-human CD279 (PD-1)

  • APC anti-human CD279 (PD-1)

  • Alexa Fluor® 647 anti-human CD279 (PD-1)

  • PerCP/Cyanine5.5 anti-human CD279 (PD-1)

  • APC/Cyanine7 anti-human CD279 (PD-1)

  • Pacific Blue™ anti-human CD279 (PD-1)

  • PE/Cyanine7 anti-human CD279 (PD-1)

  • Purified anti-human CD279 (PD-1) (Maxpar® Ready)

  • Brilliant Violet 605™ anti-human CD279 (PD-1)

  • Ultra-LEAF™ Purified anti-human CD279 (PD-1)

  • Brilliant Violet 711™ anti-human CD279 (PD-1)

  • Brilliant Violet 785™ anti-human CD279 (PD-1)

  • Brilliant Violet 510™ anti-human CD279 (PD-1)

  • Biotin anti-human CD279 (PD-1)

  • PE/Dazzle™ 594 anti-human CD279 (PD-1)

  • Alexa Fluor® 488 anti-human CD279 (PD-1)

  • PerCP anti-human CD279 (PD-1)

  • GoInVivo™ Purified anti-human CD279 (PD-1)

  • Brilliant Violet 650™ anti-human CD279 (PD-1)

  • Alexa Fluor® 700 anti-human CD279 (PD-1)

  • APC/Fire™ 750 anti-human CD279 (PD-1)

  • TotalSeq™-A0088 anti-human CD279 (PD-1)

  • TotalSeq™-B0088 anti-human CD279 (PD-1)

  • TotalSeq™-C0088 anti-human CD279 (PD-1)

  • Brilliant Violet 750™ anti-human CD279 (PD-1)

  • TotalSeq™-D0088 anti-human CD279 (PD-1)

  • PE/Fire™ 640 anti-human CD279 (PD-1)

  • PE/Cyanine5 anti-human CD279 (PD-1)

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account